PATENT COOPERATION TREATY

PCT

Translation INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference				
0000054239	FOR FURTHER ACTION	See Form PCT/IPEA/416		
International application No.	International filing date (day/month/year)	Priority date (day/month/year)		
PCT/EP2004/000237	15.01.2004	22.01.2003		
nternational Patent Classification (IPC) or natio	onal classification and IPC			
C07D 333/22				
Applicant BASF AKTIENGESELLSCH	ÆT			
This report is the international prelin under Article 35 and transmitted to the	ninary examination report, established by a applicant according to Article 36.	this International Preliminary Examining Authority		
2. This REPORT consists of a total of _	E	cluding this cover sheet.		
3. This report is also accompanied by Al	NEXES, comprising:			
a. (sent to the applicant and	to the International Bureau) a total of	sheets, as follows:		
sheets of the descrip	tion, claims and/or drawings which have h	been amended and are the basis for this report and/or see Rule 70.16 and Section 607 of the Administrative		
sheets which superso the disclosure in the Box.	ede earlier sheets, but which this Authorit international application as filed, as indi	cy considers contain an amendment that goes beyond icated in item 4 of Box No. I and the Supplemental		
b. (sent to the International I	Bureau only) a total of (indicate type and n	number of electronic carrier(s))		
related thereto, in computer	readable form only, as indicated in the S	, containing a sequence listing and/or tables Supplemental Box Relating to Sequence Listing (see		
Section 802 of the Administ	rative Instructions).			
4. This report contains indications relating	ng to the following items:			
Box No. I Basis of the	report			
Box No. II Priority				
Box No. III Non-establi	shment of opinion with regard to novelty, i	inventive step and industrial applicability		
	y of invention	11		
Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement				
\square	uments cited			
Box No. VII Certain defe	ects in the international application			
Box No. VIII Certain observations on the international application				
Date of submission of the demand	Date of completion	of this report		
	Date of completion	. or and report		
Name and mailing address of the IPEA/	Authorized officer			
Facsimile No.	Telephone No.	Telephone No.		

International application No.

PCT/EP2004/000237

Box	No. I]	Basis of the report				
1.	With	regard to	o the language, this report is based on the international application in the language in which it was filed, unless otherwise or this item.				
		which is	ort is based on translations from the original language into the following language, the language of a translation furnished for the purposes of:				
			ternational search (Rule 12.3 and 23.1(b))				
			ablication of the international application (Rule 12.4)				
2.	international preliminary examination (Rule 55.2 and/or 55.3) With regard to the elements of the international application, this report is based on (replacement sheets which have been furnished to the						
2.	recei	iving Offi report):	ice in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to				
	밁	the inte	rnational application as originally filed/furnished				
	M	the desc	ription:				
ļ		pages	1-4 as originally filed/furnished				
		pages*	received by this Authority on				
		pages*	received by this Authority on				
	\boxtimes	the clai	ms:				
		nos.	1-8 as originally filed/furnished				
		nos.*	as amended (together with any statement) under Article 19				
		nos.*	received by this Authority on				
		nos.*	received by this Authority on				
	\boxtimes	the dra					
		sheets	• /•				
		sheets*	as originally incurrence				
		sheets*					
1							
			ence listing and/or any related table(s) – see Supplemental Box Relating to Sequence Listing.				
3.			nendments have resulted in the cancellation of:				
			he description, pages				
		t	he claims, nos.				
			he drawings, sheets/figs				
			he sequence listing (specify):				
		L .	any table(s) related to sequence listing (specify):				
4.		This re	eport has been established as if (some of) the amendments annexed to this report and listed below had not been made, since ave been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).				
			he description, pages				
			he claims, nos.				
			the drawings, sheets/figs				
		1 1	the sequence listing (specify):				
			any table(s) related to sequence listing (specify):				
<u>+</u>	If it		olies, some or all of those sheets may be marked "superseded."				

International application No.
PCT/EP2004/000237

Box	r No. V	Reasoned stat	tement under Art	icle 35(2) with regard to novelty, inventive step or industrial applicability;		
1.	Statement					
	Novelty (N)		Claims	1-8		
			Claims	1-8	YES NO	
			-		_ NO	
	Inventive step (IS) Industrial applicability (IA)		Claims	1-8	_ YES	
			Claims		_ NO	
			(A) Claims	1-8	YES	
			Claims			
<u> </u>						
2.	Citations	and explanations (•			
	1.	Subject	matter of	the independent claims		
		The appl	ication r	elates to 3-methylamino-1-(2-thienyl)-1-		
propanone and acid addition salts thereof (independ			d addition salts thereof (independent			
		claim 1)	and to t	he use of these compounds (independent		
claim 3) as intermediates in the preparation of duloxetimes			∍,			
		to a corresponding method (independent claim 6).				
		Note: Pr	oduct cla	im 2 has been drafted as an independent		
				is is presumably a mistake, and it should be drafted		
			dent on c			
		-				
	2.	Prior ar	t documer	nts		
		Referenc	e is made	e to the following documents (the referen	5 0	
		numbers will be retained throughout the remainder of the				
	procedure					
		procedur	.0,.			
		D1: W	0 0004/00	0201 7 (200000 02000 02000		
1				0391 A (MERCK PATENT GMBH; NIESERT CLAUS-		
				; FABIAN KAI (DE); KRALIK), 11 March 2004	ł	
				559 (LILLY CO ELI), 21 November 1991		
				1.: "CHEMO-ENZYMATIC SYNTHESIS OF THE		
				SANT DULOXETINE AND ITS ENANTIOMER",		
		C	HIRALITY,	WILEY-LISS, NEW YORK, US, Vol. 12, No. 1	L,	
1		2	000. page	s 26-29		

International application No.
PCT/EP2004/000237

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

With regard to document D1, see Box VI below. D1 will be disregarded in the comments which follow.

3. Novelty (PCT Article 33(2)) and inventive step (PCT Article 33(3))

The compounds claimed in claims 1 and 2 are novel over documents D2 and D3 and the other prior art documents covered by the provisions of PCT Rule 64.1(b). The same applies to the use and process claims (claims 3 to 8), which relate to the use of these compounds as intermediates in the preparation of duloxetine.

Claims 1 to 8 are inventive because the processes known from the closest prior art according to D2 and D3 involve different synthesis routes. In the prior art the alcohol function is always formed first by reduction of the corresponding carbonyl precursor, before the introduction of the monomethyl amino group. The technical problem of interest, namely that of providing an alternative process for preparing duloxetine, is thus solved in a non-obvious and inventive way.

4. Industrial applicability (PCT Article 33(4))

Claims 1 to 8 in the present application are industrially applicable (PCT Article 33(4)).

International application No.
PCT/EP2004/000237

Box No. VI	Certain documents cited			
1. Certai	in published documents (Rule 70.10)			
	Application No. Patent No.	Publication date (day/month/year)	Filing date	Priority date (valid claim)
•	Autom 110.	(day/montroyear)	(day/month/year)	(day/month/year)
				:
The co	mpounds claimed in claims	s 1 and 2 are an	ticipated by d	locument D1,
	hough D1 is not regarded			
	lidity of the priority cl			
2. Non-	written disclosures (Rule 70.9)		Value - Value	
	Kind of non-written disclosure	Date of non-written dis (day/month/year	sclosure referr	Date of written disclosure ing to non-written disclosure (day/month/year)
	See supplemental			
	sheet			
1				